Sumitomo Dainippon Pharma (United States)
In research, Sumitomo Dainippon Pharma (United States) stands highest in Physical Sciences (#16,391 of 17,446 worldwide), over all time.
- World rank, all time
- #21,868 of 34,923
- Rank in United States
- #4,539 of 7,310
- Research works
- 402 ▲ 94% vs 2018-21
- Citations
- 7.3k 18.2 per fractional work
- Top-10% rate
- 8.6% all institutions 10.0%
- vs its own fields
- 0.82× 1.00× is exactly expected
- Open access
- 66% world 40%
- International
- 45% world 18%
What is Sumitomo Dainippon Pharma (United States) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| Physical SciencesDomain | #16,391 of 17,446 | 5.8% | 189 |
Each strip is that field's whole ranked pool, with the notch where Sumitomo Dainippon Pharma (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no average mark, because the average differs by field (from about 6% in Dentistry to 21% in Economics).
Which fields of science does Sumitomo Dainippon Pharma (United States) work in?
In 2022-now, 51% of research at Sumitomo Dainippon Pharma (United States) is in Health Sciences, 32% in Life Sciences. Its largest fields are Medicine (49%), Biochemistry, Genetics and Molecular Biology (16%), Neuroscience (6%). It does 2.0× the world's share of Life Sciences.
Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.
Its 4 domains and 23 fields, with their numbers
- Health Sciences3051.2%
- Medicine2948.8%
- Health Professions11.4%
- Veterinary00.6%
- Dentistry00.3%
- Nursing00.1%
- Life Sciences1932.0%
- Social Sciences610.7%
- Physical Sciences46.2%
- Chemistry11.8%
- Engineering11.5%
- Mathematics11.1%
- Computer Science00.6%
- Environmental Science00.5%
- Materials Science00.5%
- Earth and Planetary Sciences00.1%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 7.5×. Every wedge is a field page.
All 23 fields, with their numbers
- Pharmacology, Toxicology and Pharmaceutics7.45×2 works
- Immunology and Microbiology5.97×4 works
- Veterinary4.19×0 works
- Neuroscience3.97×4 works
- Biochemistry, Genetics and Molecular Biology3.08×10 works
- Medicine2.54×28 works
- Economics, Econometrics and Finance1.35×2 works
- Chemistry1.15×1 works
- Mathematics0.93×1 works
- Business, Management and Accounting0.90×2 works
- Dentistry0.59×0 works
- Health Professions0.54×1 works
- Decision Sciences0.35×0 works
- Nursing0.29×0 works
- Psychology0.28×0 works
- Social Sciences0.27×2 works
- Materials Science0.14×0 works
- Engineering0.10×1 works
- Environmental Science0.10×0 works
- Arts and Humanities0.10×0 works
- Agricultural and Biological Sciences0.09×0 works
- Earth and Planetary Sciences0.09×0 works
- Computer Science0.08×0 works
- Pharmacology, Toxicology and Pharmaceutics 7.5×
- Immunology and Microbiology 6.0×
- Veterinary 4.2×
- Neuroscience 4.0×
- Biochemistry, Genetics and Molecular Biology 3.1×
- Medicine 2.5×
- Economics, Econometrics and Finance 1.4×
- Chemistry 1.1×
- Mathematics 0.9×
- Business, Management and Accounting 0.9×
- Dentistry 0.6×
- Health Professions 0.5×
- Decision Sciences 0.3×
- Nursing 0.3×
- Psychology 0.3×
- Social Sciences 0.3×
- Materials Science 0.1×
- Engineering 0.1×
- Environmental Science 0.1×
- Arts and Humanities 0.1×
- Agricultural and Biological Sciences 0.1×
- Earth and Planetary Sciences 0.1×
- Computer Science 0.1×
Who are the top researchers at Sumitomo Dainippon Pharma (United States)?
Ranked on the quality score, Alex Avdeef, Jason M. Foulks and Oksana Tsinman lead among researchers whose main affiliation is Sumitomo Dainippon Pharma (United States).
- 1
Alex Avdeef
United States · #396,749 worldwide 13k citations · 199 works
- 2
Jason M. Foulks
United States · #1,155,022 worldwide 2.5k citations · 145 works
- 3
Oksana Tsinman
United States · #1,283,270 worldwide 2k citations · 30 works
- 4
Konstantin Tsinman
United States · #2,126,051 worldwide 891 citations · 26 works
- 5
Sadao Hirae
United States · #4,060,976 worldwide 149 citations · 16 works
- 6
Antonio Castagna
United States · #4,502,406 worldwide 451 citations · 68 works
- 7
Hajime Shirakawa
United States · #4,513,687 worldwide 122 citations · 18 works
- 8
Gil D. Fine
United States · #4,590,169 worldwide 207 citations · 22 works
Which keywords describe research at Sumitomo Dainippon Pharma (United States)?
By fractional works in 2022-now, weighted toward what it does more of than the world: Metabolic Syndrome, Cancer Therapy, Antipsychotic Drugs, Neurocognitive Deficits, Innate Immunity, Epidemiology, Urinary Incontinence and Neurological Disorders.
- Uterine Fibroids
- Signal Transduction
- Health-related Quality of Life
- Surgical Treatment
- Clinical Guidelines
- Stress
- Neurobiology
- Benign Prostatic Hyperplasia
- Tumor Microenvironment
- Hormone Therapy
- Clinical Trials
- Urinary Incontinence
- Corporate Governance
- Innate Immunity
- Financial Performance
- Neurological Disorders
- Cancer
- Antipsychotic Drugs
- Cancer Therapy
- Epidemiology
- Metabolic Syndrome
- Inflammation
- Oxidative Stress
- Neurocognitive Deficits
- Immunotherapy
- Depression
- Genetic Mutations
- Chemotherapy
- Prognostic Factors
- Biomarkers
- Cognitive Function
- Treatment Guidelines
- Genetic Variation
- Lower Urinary Tract Symptoms
- Parkinson's Disease
- Breast Cancer
- Prostate Cancer
- Cell Signaling
- Monoclonal Antibodies
- Hematopoietic Stem Cells
Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Metabolic Syndrome4▲ 8.7×6 topics
- Epidemiology4▲ 1.70×12 topics
- Inflammation3▲ 2.3×14 topics
- Cancer Therapy3▲ 8.1×7 topics
- Oxidative Stress3▲ 2.7×9 topics
- Antipsychotic Drugs2▲ 106×1 topic
- Neurocognitive Deficits2▲ 106×1 topic
- Cancer2▲ 2.8×9 topics
- Immunotherapy2▲ 4.8×7 topics
- Neurological Disorders2▲ 5.8×7 topics
- Depression2▲ 3.5×7 topics
- Financial Performance2▲ 5.6×3 topics
- Genetic Mutations2▲ 6.9×5 topics
- Innate Immunity2▲ 9.6×5 topics
- Chemotherapy2▲ 4.1×11 topics
- Corporate Governance2▲ 3.9×3 topics
- Prognostic Factors2▲ 6.5×5 topics
- Urinary Incontinence2▲ 37×2 topics
- Biomarkers2▲ 3.9×7 topics
- Clinical Trials2▲ 4.0×6 topics
- Cognitive Function2▲ 15×5 topics
- Hormone Therapy2▲ 33×3 topics
- Treatment Guidelines2▲ 13×3 topics
- Tumor Microenvironment2▲ 6.0×5 topics
- Genetic Variation2▲ 12×3 topics
- Benign Prostatic Hyperplasia1▲ 71×1 topic
- Lower Urinary Tract Symptoms1▲ 71×1 topic
- Neurobiology1▲ 9.3×4 topics
- Parkinson's Disease1▲ 9.8×7 topics
- Stress1▲ 6.6×3 topics
- Breast Cancer1▲ 8.6×5 topics
- Clinical Guidelines1▲ 7.7×3 topics
- Prostate Cancer1▲ 17×2 topics
- Surgical Treatment1▲ 12×2 topics
- Cell Signaling1▲ 13×5 topics
- Health-related Quality of Life1▲ 8.5×2 topics
- Monoclonal Antibodies1▲ 22×2 topics
- Signal Transduction1▲ 13×2 topics
- Hematopoietic Stem Cells1▲ 22×2 topics
- Uterine Fibroids1▲ 65×1 topic
Which research topics does Sumitomo Dainippon Pharma (United States) publish most on?
By volume in 2022-now: Schizophrenia research and treatment, Urinary Bladder and Prostate Research, Uterine Myomas and Treatments and Biosimilars and Bioanalytical Methods.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Schizophrenia research and treatment Psychiatry and Mental health 2 works
- 2 Urinary Bladder and Prostate Research Urology 1 works
- 3 Uterine Myomas and Treatments Obstetrics and Gynecology 1 works
- 4 Biosimilars and Bioanalytical Methods Immunology 1 works
- 5 Bipolar Disorder and Treatment Psychiatry and Mental health 1 works
- 6 Endometriosis Research and Treatment Reproductive Medicine 1 works
- 7 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 1 works
- 8 Neurotransmitter Receptor Influence on Behavior Cellular and Molecular Neuroscience 1 works
- 9 Ubiquitin and proteasome pathways Molecular Biology 1 works
- 10 Acute Myeloid Leukemia Research Hematology 1 works
How open and international is its research?
Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 40% of research is openly available.
World: 18% is written across borders.
How has Sumitomo Dainippon Pharma (United States)'s research output changed?
Output in 2022-2025 was 94% higher than in 2018-2021.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Sumitomo Dainippon Pharma (United States) as a percentage of every work published that year, 0.00032% in 2024.
Fractional works of Sumitomo Dainippon Pharma (United States) over all fractional works that year. How the balance of science has shifted.
Other research institutions in Marlborough
- Boston Scientific (United States)
- Sunovion (United States)
- Hologic (United States)
- Hottinger Baldwin Messtechnik (United States)
- Advanced Cell Technology (United States)
- Phio Pharmaceuticals (United States)
- CardioFocus (United States)
- Verax Biomedical (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.
Discussion
Ask a question or share a note about Sumitomo Dainippon Pharma (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.
